Trials / Terminated
TerminatedNCT03846128
Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 6 (actual)
- Sponsor
- University Hospital, Rouen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients treated on the first line of Sunitinib-targeted therapy for metastatic kidney cancer. Collection of additional blood tubes during routine blood tests for patient follow-up, to evaluate the plasma concentration of Sunitinib and its active metabolite desethyl-Sunitinib (DES)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | blood sample | blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1 |
Timeline
- Start date
- 2019-06-03
- Primary completion
- 2021-10-08
- Completion
- 2021-10-08
- First posted
- 2019-02-19
- Last updated
- 2026-04-14
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03846128. Inclusion in this directory is not an endorsement.